Eli Lilly and Company announced plans to begin a new pragmatic study of bamlanivimab (LY-CoV555) in high-risk patients with COVID-19, in collaboration with major local institutions in the state of New Mexico.
Merck and Eisai announced that the pivotal Phase 3 KEYNOTE-775/Study 309 trial evaluating the investigational use of KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) and its secondary efficacy endpoint of objective response rate (ORR) in patients with advanced endometrial cancer following at least one prior platinum-based regimen.
Novartis announced updated median overall survival (OS) results for Kisqali (ribociclib) in combination with endocrine therapy, marking the longest survival data ever reported in premenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+HER2-) metastatic breast cancer.
AstraZeneca and University of Oxford said that interim analysis of a phase 3 programme of the AZD1222 vaccine candidate (also called ChAdOx1 nCoV-19) is 70.4% effective in preventing symptomatic Covid-19 for more than 14 days after its second dose.
Inovio Pharmaceuticals has dosed its first subject in phase 2 segment of its INNOVATE Phase 2/3 Clinical Trial for Covid-19 DNA vaccine candidate.
Pfizer and Sangamo Therapeutics, a genomic medicines company, announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec (SB-525 or PF-07055480), an investigational gene therapy for patients with severe hemophilia A.
Sinovac Life Sciences (Sinovac LS), a subsidiary of Sinovac, has received up to $500m in funding for the development of its Covid-19 vaccine candidate.
Dr. Reddy’s Laboratories and Russian Direct Investment Fund (RDIF) announced that they have commenced adaptive phase 2/3 clinical trials for Sputnik V vaccine in India after receiving the necessary clearance from the Central Drugs Laboratory, Kasauli, India.
Biopharmaceutical company Amgen, along with two other drugmakers Takeda and UCB, has enrolled the first patient in a global platform trial of hospitalised patients with Covid-19.
Haoma Medica announced the completion of a first-in-human trial for NaQuinate, a naphthoquinone carboxylic acid, which is being developed as a novel orally administered therapeutic for osteoporosis.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.